Preclinical studies in mice have shown that TP53 mutations in CLL not only exacerbate the course of the disease, resulting in high tumor burden, but also have a negative impact on the successful transplantation of T- cells. The gene discussed is TP53; the disease is B-cell chronic lymphocytic leukemia.